A variety of biologic DMARDs now exist for the treatment of rheumatoid arthritis, but we don’t really know how these drugs function in vivo. Can time-lapse intravital imaging distinguish the modes of action of DMARDs by comparing response to joint destruction in mouse models of arthritis?
This is a preview of subscription content, log in via an institution to check access.
References
Shim, J. H., Stavre, Z. & Gravallese, E. M. Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications. Calcif. Tissue Int. 102, 533–546 (2018).
Burmester, G. R. et al. Managing rheumatic and musculoskeletal diseases — past, present and future. Nat. Rev. Rheumatol. 13, 443–448 (2017).
Matsuura, Y. et al. In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2017-212880 (2018).
Dimitroulas, T. et al. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun. Rev. 12, 958–966 (2013).
Robling, A. D. & Stout, S. D. Morphology of the drifting osteon. Cells Tissues Organs 164, 192–204 (1999).
Kliwinski, C. et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J. Autoimmun. 25, 165–171 (2005).
Kikuta, J. et al. Dynamic visualization of RANKL and Th17-mediated osteoclast function. J. Clin. Invest. 123, 866–873 (2013).
Axmann, R. et al. CTLA-4 directly inhibits osteoclast formation. Ann. Rheum. Dis. 67, 1603–1609 (2008).
Schett, G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res. Ther. 9, 203 (2007).
Cutolo, M. et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res. Ther. 11, R176 (2009).
Acknowledgements
The authors thank S. Paolino, S. Soldano, R. Brizzolara and staff members at the Research Laboratory and Division of Clinical Rheumatology of the University of Genova for their support in the compilation of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.C. declares he has received university research funds from Actelion Pharmaceuticals Ltd, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, and Horizon Pharma. A.S. declares no competing interests.
Rights and permissions
About this article
Cite this article
Cutolo, M., Sulli, A. Testing the anti-osteoclastic function of biologic DMARDs. Nat Rev Rheumatol 14, 446–448 (2018). https://doi.org/10.1038/s41584-018-0046-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0046-0
- Springer Nature Limited